All PlansCoverageLow impact
Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Blue Cross & Blue Shield of Mississippi·Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage criteria for microarray-based gene expression profile (GEP) testing used for risk stratification in multiple myeloma patients. The policy provides detailed background information on multiple myeloma and GEP testing technology but does not specify coverage determinations or billing requirements.
Action Required
Review the policy document to understand GEP testing for multiple myeloma risk stratification. Monitor for subsequent updates that may include specific coverage criteria, prior authorization requirements, or billing codes for this testing technology.